9 withdrawn. 9 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Withdrawn 9 |
| Phase 1 | 2 | Withdrawn 2 |
| Phase 3 | 1 | Withdrawn 1 |
Follow Vasculitis: new trials by email Literature Review of Vasculitis trials Research Report on Vasculitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ivarmacitinib for Refractory Behcet's Syndrome Ivarmacitinib - Behcet's Syndrome | Phase 2 | Withdrawn | Liu Tian | 2026-06-01 | 2026-07-10 | |
| PROphylaxis for paTiEnts at Risk of COVID-19 infecTion Hydroxychloroquine Sulfate 200 MG - COVID-19 | Phase 2 / Phase 3 | Withdrawn | Cambridge University Hospitals NHS Foundation Trust | 2020-09-01 | 2021-03-08 | |
| Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders denosumab - Osteoporosis, Juvenile Rheumatoid Arthritis | Phase 1 / Phase 2 | Withdrawn | Indiana University | 2019-08-01 | 2019-12-06 | |
| Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease Canakinumab - Kawasaki Disease | Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2016-11-15 | 2017-02-17 | |
| BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis Blisibimod, Placebo - Granulomatosis With Polyangiitis, Microscopic Polyangiitis | Phase 2 | Withdrawn | Anthera Pharmaceuticals | 2014-12-01 | 2015-07-30 | |
| Retinoids in ANCA Small Vessel Vasculitis: Silencing Autoantigens Retinoic acid, Standard of care - Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Phase 2 | Withdrawn | University of North Carolina, Chapel Hill | 2012-01-01 | 2017-02-23 | |
| Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab Standard of care treatment, eculizumab - Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Phase 2 | Withdrawn | University of North Carolina, Chapel Hill | 2011-05-01 | 2017-02-23 | |
| A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome / Muckle-Wells Syndrome and Behcet's Disease XOMA 052 - Muckle Wells Syndrome, Autoinflammatory | Phase 1 / Phase 2 | Withdrawn | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 2010-08-27 | 2017-07-02 | |
| Cardiovascular Risk Markers and Response to Statins After Kawasaki Disease pravastatin - Kawasaki Disease | Phase 2 | Withdrawn | Pontificia Universidad Catolica de Chile | 2006-04-01 | 2016-05-24 |
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (3) · Behcet Syndrome (2) · Mucocutaneous Lymph Node Syndrome (2) · Arthritis (1) · Arthritis, Juvenile (1) · COVID-19 (1) · Coronary Aneurysm (1) · Cryopyrin-Associated Periodic Syndromes (1) · Dermatomyositis (1) · Granulomatosis with Polyangiitis (1) · Microscopic Polyangiitis (1) · Osteoporosis (1)
Cardiovascular Diseases (9) · Vascular Diseases (9) · Skin Diseases (8) · Skin and Connective Tissue Diseases (8) · Skin Diseases, Vascular (7) · Immune System Diseases (5) · Autoimmune Diseases (4) · Systemic Vasculitis (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Eye Diseases (2) · Genetic Diseases, Inborn (2) · Hemic and Lymphatic Diseases (2) · Hereditary Autoinflammatory Diseases (2) · Lung Diseases (2)
AMG623 peptibody (1) · Adenosine Triphosphate (1) · Azathioprine (1) · Cyclophosphamide (1) · Denosumab (1) · Hydroxychloroquine (1) · Mycophenolic Acid (1) · Pravastatin (1) · Standard of Care (1) · Tretinoin (1) · canakinumab (1) · eculizumab (1) · gevokizumab (1) · ivarmacitinib (1)
University of North Carolina, Chapel Hill (2) · Anthera Pharmaceuticals (1) · Cambridge University Hospitals NHS Foundation Trust (1) · Indiana University (1) · Liu Tian (1) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (1) · Novartis Pharmaceuticals (1) · Pontificia Universidad Catolica de Chile (1)
United States (4) · Chile (1) · China (1)
Patrick H Nachman, MD (2) · Arturo Borzutzky, MD (1) · Erik Imel, MD (1) · Miguel Gutierrez, MD (1) · Thomas Hiemstra, PhD (1)
P01DK058335 (2)